(Q40513403)

English

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation

scientific article published on February 1995

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

Europe PubMed Central

Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

C P Rains

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

H M Bryson

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

A Fitton

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

1 February 1995

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

255-279

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibitory effect of cabergoline on the development of estrogen-induced prolactin-secreting adenomas of the pituitary

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabergoline in the long-term therapy of hyperprolactinemic disorders.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Compliance in hypertension: daily v twice daily

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacological characterization of the D2 dopamine receptor negatively coupled with adenylate cyclase in rat anterior pituitary

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lactation suppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine agonists and pituitary tumor shrinkage

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects on pseudopregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progress in the management of hyperprolactinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. European Multicentre Cabergoline Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pleuropulmonary disease associated with dopamine agonist therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oral cabergoline. Single-dose inhibition of puerperal lactation

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic applications of bromocriptine in endocrine and neurological diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diagnosis and management of pituitary tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ten year follow up of microprolactinoma treated by transsphenoidal surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between inhibitory effect on prolactin secretion and antitumor activity of new ergoline compounds on DMBA-induced tumors in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. European Multicentre Study Group for Cabergoline in Lactation Inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Natural history of hyperprolactinemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopaminergic treatments for hyperprolactinaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-resolution computed tomographic appearance of the intrasellar contents in women of childbearing age

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bromocriptine in pregnancy: safety aspects

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LHRH-induced gonadotropin release before and after short-term therapy with cabergoline in hyperprolactinaemic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Surveillance of bromocriptine in pregnancy

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective and extremely long inhibition of prolactin release in man by 1-ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta- carbonyl)-urea-diphosphate (FCE 21336).

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent, cabergoline

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Osteocalcin levels in patients with microprolactinoma before and during medical treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of cabergoline in plasma and urine by high-performance liquid chromatography with electrochemical detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Excretion balance and urinary metabolic pattern of [3H]cabergoline in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabergoline: long-acting oral treatment of hyperprolactinemic disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical therapy of hyperprolactinemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New perspectives in medical management of hyperprolactinemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/7729332

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-199549020-00009

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40513403&oldid=2203749627"